ImmuCell Corporation (ICCC) and Synlogic Inc. (NASDAQ:SYBX) Comparison side by side

Both ImmuCell Corporation (NASDAQ:ICCC) and Synlogic Inc. (NASDAQ:SYBX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmuCell Corporation 10.99M 3.47 2.32M -0.42 0.00
Synlogic Inc. 2.52M 78.92 48.44M -2.29 0.00

Table 1 highlights ImmuCell Corporation and Synlogic Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 represents ImmuCell Corporation (NASDAQ:ICCC) and Synlogic Inc. (NASDAQ:SYBX)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
ImmuCell Corporation -21.11% -6.7% -4.6%
Synlogic Inc. -1,922.22% -39.1% -34.7%

Risk & Volatility

ImmuCell Corporation has a 1.25 beta, while its volatility is 25.00% which is more volatile than Standard and Poor’s 500. Competitively, Synlogic Inc.’s 142.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 2.42 beta.


The Current Ratio of ImmuCell Corporation is 3.2 while its Quick Ratio stands at 2.1. The Current Ratio of rival Synlogic Inc. is 15.2 and its Quick Ratio is has 15.2. Synlogic Inc. is better equipped to clear short and long-term obligations than ImmuCell Corporation.

Institutional and Insider Ownership

The shares of both ImmuCell Corporation and Synlogic Inc. are owned by institutional investors at 14.1% and 82.2% respectively. Insiders held 6.3% of ImmuCell Corporation shares. Competitively, insiders own roughly 0.2% of Synlogic Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ImmuCell Corporation -3.63% -11.15% -9.35% 7.5% -5.06% -0.3%
Synlogic Inc. -10.16% 1.73% -3.29% -14.29% -20.89% 17.26%

For the past year ImmuCell Corporation had bearish trend while Synlogic Inc. had bullish trend.


ImmuCell Corporation beats on 7 of the 10 factors Synlogic Inc.

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.

Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.